MetLife Investment Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

MetLife Investment Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$407K	Sell	20,761 -314	-1%	-$7.68K	﹤0.01%	1847
2025 Q4	$564K	Sell	21,075 -2,018	-9%	-$52K	﹤0.01%	1736
2025 Q3	$615K	Hold	23,093	–	–	﹤0.01%	1703
2025 Q2	$530K	Hold	23,093	–	–	﹤0.01%	1653
2025 Q1	$669K	Sell	23,093 -359	-2%	-$11.5K	﹤0.01%	1563
2024 Q4	$871K	Buy	23,452 +845	+4%	+$38.6K	﹤0.01%	1491
2024 Q3	$1.1M	Hold	22,607	–	–	0.01%	1342
2024 Q2	$904K	Buy	22,607 +3,090	+16%	+$128K	0.01%	1394
2024 Q1	$857K	Sell	19,517 -950	-5%	-$49.1K	0.01%	1385
2023 Q4	$1.27M	Hold	20,467	–	–	0.01%	1178
2023 Q3	$941K	Hold	20,467	–	–	0.01%	1262
2023 Q2	$1.18M	Hold	20,467	–	–	0.01%	1172
2023 Q1	$768K	Hold	20,467	–	–	0.01%	1379
2022 Q4	$573K	Hold	20,467	–	–	﹤0.01%	1555
2022 Q3	$575K	Hold	20,467	–	–	﹤0.01%	1534
2022 Q2	$712K	Hold	20,467	–	–	0.01%	1420
2022 Q1	$735K	Buy	20,467 +8,664	+73%	+$246K	﹤0.01%	1528
2021 Q4	$275K	Hold	11,803	–	–	﹤0.01%	1855
2021 Q3	$224K	Hold	11,803	–	–	﹤0.01%	2014
2021 Q2	$238K	Hold	11,803	–	–	﹤0.01%	2043
2021 Q1	$216K	Sell	11,803 -6,402	-35%	-$119K	﹤0.01%	2014
2020 Q4	$366K	Hold	18,205	–	–	﹤0.01%	1638
2020 Q3	$341K	Hold	18,205	–	–	﹤0.01%	1564
2020 Q2	$409K	Hold	18,205	–	–	﹤0.01%	1491
2020 Q1	$270K	Hold	18,205	–	–	﹤0.01%	1534
2019 Q4	$351K	Hold	18,205	–	–	﹤0.01%	1649
2019 Q3	$361K	Hold	18,205	–	–	﹤0.01%	1591
2019 Q2	$384K	Hold	18,205	–	–	﹤0.01%	1635
2019 Q1	$372K	Hold	18,205	–	–	﹤0.01%	1630
2018 Q4	$362K	Hold	18,205	–	–	﹤0.01%	1557
2018 Q3	$350K	Hold	18,205	–	–	﹤0.01%	1757
2018 Q2	$278K	Hold	18,205	–	–	﹤0.01%	1749
2018 Q1	$341K	Hold	18,205	–	–	﹤0.01%	1610
2017 Q4	$350K	Buy	+18,205	New	+$340K	﹤0.01%	1618

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

MetLife Investment Management's AMPH Position: Q1 2026 in Review

MetLife Investment Management reduced its Amphastar Pharmaceuticals (AMPH) stake by 1.5% in Q1 2026, selling an estimated $7.68K and leaving 20,761 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #1847.

MetLife Investment Management first reported a position in AMPH in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.27M in Q4 2023. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

MetLife Investment Management held 20,761 shares of Amphastar Pharmaceuticals worth $407K as of Q1 2026.
MetLife Investment Management sold 314 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $7.68K.
Amphastar Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1847 holding.
MetLife Investment Management first reported a position in Amphastar Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
MetLife Investment Management's Amphastar Pharmaceuticals position peaked at $1.27M in Q4 2023.
215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.